Previous close | 0.1200 |
Open | 0.1200 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expiry date | 2026-01-16 |
Day's range | 0.1200 - 0.1200 |
Contract range | N/A |
Volume | |
Open interest | N/A |
First Quarter 2024 Insurance Revenue growth of 8% year-over-year First Quarter 2024 GAAP Net Loss from Continuing Operations of $23.2 million versus First Quarter 2023 loss of $79.7 million First Quarter Adjusted EBITDA profitability of $6.8 million versus prior period loss of $37.5 million Improves 2024 guidance to Insurance Revenue of $1.30 billion - $1.35 billion and Adjusted EBITDA profitability of $10 million - $30 million Maintains strong liquidity position and view that Company has suffic
FRANKLIN, Tenn., May 01, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced its participation in the following investor conferences: CEO, Andrew Toy, and CFO, Peter Kuipers, will participate at the Bank of America 2024 Healthcare Conference on Wednesday, May 15, 2024.CEO, Andrew Toy, will present at
FRANKLIN, Tenn., April 30, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, announced today that effective April 29, 2024, the Talent and Compensation Committee of the Company’s Board of Directors granted a restricted stock unit award (the “RSUs”) to Peter Kuipers, who will be the Company’s new Chief Financial Officer effective a